Darifenacin or darifenacin hydrobromide

BMS-754807 is an inhibitor of the insulin receptor (InsR) and IGF-1R that exhibits anticancer chemotherapeutic activity. BMS-754807 enhances the efficacy of other co-administered chemotherapeutics, decreasing levels of activated Akt, increasing

BMS-754807 is an inhibitor of the insulin receptor (InsR) and IGF-1R that exhibits anticancer chemotherapeutic activity. BMS-754807 enhances the efficacy of other co-administered chemotherapeutics, decreasing levels of activated Akt, increasing

BMS-754807 is an inhibitor of the insulin receptor (InsR) and IGF-1R that exhibits anticancer chemotherapeutic activity. BMS-754807 enhances the efficacy of other co-administered chemotherapeutics, decreasing levels of activated Akt, increasing

InformationIsoliquiritigenin Isoliquiritigenin, an anti-tumor flavonoid from the root of Glycyrrhiza glabra, inhibits aldose reductase with an IC50 of 320 nM.In vitroIsoliquiritigenin may be effective in preventing diabetic complications through

Store at -20°C. Store under desiccating conditions.

A hydroxamate-based inhibitor of HDACs with an IC₅₀ value of 30 nM inhibits the growth of colon, breast, prostate, and non-small cell lung cancer cell lines at concentrations of less than 1 &microM augments the actions of fludarabine

A hydroxamate-based inhibitor of HDACs with an IC₅₀ value of 30 nM inhibits the growth of colon, breast, prostate, and non-small cell lung cancer cell lines at concentrations of less than 1 &microM augments the actions of fludarabine

A hydroxamate-based inhibitor of HDACs with an IC₅₀ value of 30 nM inhibits the growth of colon, breast, prostate, and non-small cell lung cancer cell lines at concentrations of less than 1 &microM augments the actions of fludarabine

Liquiritigenin is a flavonoid and an estrogenic compound found in licorice ( Glycyrrhizae radix ) root extract and several other plants. Application Liquiritigenin has been used: to study its inhibitory effect on tumor metastasis in the treatment

An HDAC inhibitor that selectively targets HDACs 4 and 5 (IC₅₀s = 12 and 4 nM, respectively) over other HDACs (IC₅₀s = 56, 320, 850, 880, and 1,280 for HDACs 6, 1, 11, 2, and 8, respectively) displays enhanced cytotoxic

MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to

MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to